ArticleScientific reports2025
SIRT1 antisense long noncoding RNA attenuates interleukin-1β-induced osteoarthritic gene expression in human chondrocytes through its mRNA interaction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- SIRT1 as a Key Regulator in Rheumatic Diseases: Integrating Molecular Insights with Traditional Chinese Medicine Approaches.Journal of inflammation research · 2026Review
- Epigenetic regulation in osteoarthritis: recent updates and emerging mechanisms.Frontiers in genetics · 2026Review
- Energy crisis and cartilage collapse: metabolic reprogramming of chondrocytes in osteoarthritis.Frontiers in immunology · 2026Review
- Molecular mediators of motion: RNA-RBP networks in exercise-induced osteoarthritis protection.Frontiers in genetics · 2026Review
- The protective role of dexmedetomidine against anaesthetics-induced neurotoxicity through downregulating miR-34a.Journal of neurovirology · 2025Article
- Structure and Function of the Extracellular Matrix in Normal and Pathological Conditions: Looking at the Bicuspid Aortic Valve.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies demonstrated the role of antisense long noncoding RNAs (AS lncRNAs) in regulating gene expression at the transcriptional or translational level. In this study, we assessed the effects of sirtuin 1 (SIRT1) AS lncRNA overexpression and inhibition, along with overexpression of miR-34a, on interleukin (IL)-1β-induced gene expression alterations in human chondrocytes, aiming to understand its role in human chondrocytes. We analyzed gene expression alterations using real-time PCR and assessed SIRT1 protein level alterations through western blotting. IL-1β stimulation significantly upregulated A disintegrin and metalloproteinase with thrombospondin motif 5 (ADAMTS-5) and matrix metalloproteinase 13 (MMP-13). SIRT1 AS lncRNA overexpression significantly inhibited IL-1β-induced upregulation of these genes, whereas SIRT1 AS lncRNA inhibition further increased their expression. Moreover, overexpression of miR-34a significantly increased IL-1β-induced upregulation of ADAMTS-5 and MMP-13 which were rescued by over expression of SIRT1 AS lncRNA. SIRT1 protein levels were significantly increased by SIRT1 AS lncRNA overexpression and significantly reduced by its inhibition. Ribonuclease protection assay indicated the complete binding of SIRT1 AS lncRNA to SIRT1 mRNA. In the osteoarthritis (OA) cartilage, SIRT1 AS lncRNA expression was significantly reduced compared with that in normal cartilage. Our observations indicate that the binding of SIRT1 AS lncRNA to SIRT1 mRNA may suppress IL-1β-induced expression of cartilage-degrading enzymes. Therefore, SIRT1 AS lncRNA may be a novel therapeutic target for OA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.